ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification

Gene fusions prevalent in prostate cancer (CaP) lead to the elevated expression of the ERG proto-oncogene. ERG activation present in 50–70% of prostate tumors underscores one of the most common oncogenic alterations in CaP. Despite numerous reports of gene fusions and mRNA expression, ERG oncoprotein status in CaP still remains to be defined. Furthermore, development of ERG protein-based assays may provide a new dimension to evaluation of gene fusions involving diverse androgen-regulated promoters and the ERG protein-coding sequence. Through exhaustive evaluations of 132 whole-mount prostates (261 tumor foci and over 200 000 benign glands) for the ERG oncoprotein nuclear expression, we demonstrated 99.9% specificity for detecting prostate tumor cells using a highly specific anti-ERG monoclonal antibody. The ERG oncoprotein expression correlated well with fusion transcript or gene fusion in randomly selected specimens. Strong concordance of ERG-positive foci of prostatic intraepithelial neoplasia (PIN) with ERG-positive carcinoma (82 out of 85 sections with PIN, 96.5%) affirms the biological role of ERG in clonal selection of prostate tumors in 65% (86 out of 132) of patients. Conversely, ERG negative PINs were associated with ERG-negative carcinoma. Taken together, the homogeneous and strong ERG expression detected in individual tumors establishes the potential for ERG oncoprotein-based stratification of CaP.

[1]  E. Dejana,et al.  Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. , 2008, Blood.

[2]  W. Gerald,et al.  TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. , 2009, Cancer research.

[3]  Pier Paolo Pandolfi,et al.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.

[4]  P. Nelson,et al.  A causal role for ERG in neoplastic transformation of prostate epithelium , 2008, Proceedings of the National Academy of Sciences.

[5]  Chen Sun,et al.  Delineation of TMPRSS2-ERG Splice Variants in Prostate Cancer , 2008, Clinical Cancer Research.

[6]  E. Baldi,et al.  Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: Preliminary results , 2009, Journal of endocrinological investigation.

[7]  D. Watson,et al.  Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. , 2003, The American journal of pathology.

[8]  S. Srivastava,et al.  Mapping of TMPRSS2–ERG fusions in the context of multi-focal prostate cancer , 2008, Modern Pathology.

[9]  M. Teitell,et al.  ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells , 2009, Proceedings of the National Academy of Sciences.

[10]  R. Shah,et al.  Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. , 2007, Cancer research.

[11]  R. Eeles,et al.  Diversity of TMPRSS2-ERG fusion transcripts in the human prostate , 2007, Oncogene.

[12]  S. Dhanasekaran,et al.  A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. , 2008, Cancer research.

[13]  M. Rubin,et al.  TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. , 2007, Urology.

[14]  M. Gerstein,et al.  N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. , 2009, Neoplasia.

[15]  C. Sander,et al.  Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis , 2009, Nature Genetics.

[16]  A. Chinnaiyan,et al.  Recurrent gene fusions in prostate cancer , 2008, Nature Reviews Cancer.

[17]  Rodrigo Lopez,et al.  Clustal W and Clustal X version 2.0 , 2007, Bioinform..

[18]  Botoul Maqsodi,et al.  Evaluation of the branched-chain DNA assay for measurement of RNA in formalin-fixed tissues. , 2007, The Journal of molecular diagnostics : JMD.

[19]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[20]  P. Remy,et al.  Xl erg: Expression pattern and overexpression during development plead for a role in endothelial cell differentiation , 1999, Developmental dynamics : an official publication of the American Association of Anatomists.

[21]  V. Srikantan,et al.  Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome , 2005, Oncogene.

[22]  S. Srivastava,et al.  TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation , 2008, Oncogene.

[23]  P. Humphrey,et al.  Immunohistochemical Stains for p63 and α-Methylacyl-CoA Racemase, Versus a Cocktail Comprising Both, in the Diagnosis of Prostatic Carcinoma: A Comparison of the Immunohistochemical Staining of 430 Foci in Radical Prostatectomy and Needle Biopsy Tissues , 2005, The American journal of surgical pathology.

[24]  I. Kola,et al.  Detailed mapping of the ERG-ETS2 interval of human chromosome 21 and comparison with the region of conserved synteny on mouse chromosome 16. , 2004, Gene.

[25]  R. Henrique,et al.  TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. , 2006, Neoplasia.

[26]  C. Cooper,et al.  ETS gene fusions in prostate cancer , 2009, Nature Reviews Urology.

[27]  R. Shah,et al.  Role of the TMPRSS2-ERG gene fusion in prostate cancer. , 2008, Neoplasia.

[28]  M. Rubin,et al.  TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion , 2006, The American journal of surgical pathology.

[29]  J. Tchinda,et al.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.

[30]  Graham J. Lieschke,et al.  The role of the ETS factor erg in zebrafish vasculogenesis , 2009, Mechanisms of Development.